BACKGROUND AND PURPOSE: Among several pharmacological properties, analgesia is the most common feature shared by either opioid or cannabinoid systems. Cannabinoids and opioids are distinct drug classes that have been historically used separately or in combination to treat different pain states. In the present study, we characterized the signal transduction pathways mediated by cannabinoid CB(2) and µ-opioid receptors in quiescent and LPS-stimulated murine microglial cells. EXPERIMENTAL APPROACH: We examined the effects of µ-opioid and CB(2) receptor stimulation on phosphorylation of MAPKs and Akt and on IL-1β, TNF-α, IL-6 and NO production in primary mouse microglial cells. KEY RESULTS: Morphine enhanced release of the proinflammatory cytokines, IL-1β, TNF-α, IL-6, and of NO via µ-opioid receptor in activated microglial cells. In contrast, CB(2) receptor stimulation attenuated morphine-induced microglial proinflammatory mediator increases, interfering with morphine action by acting on the Akt-ERK1/2 signalling pathway. CONCLUSIONS AND IMPLICATIONS: Because glial activation opposes opioid analgesia and enhances opioid tolerance and dependence, we suggest that CB(2) receptors, by inhibiting microglial activity, may be potential targets to increase clinical efficacy of opioids.
BACKGROUND AND PURPOSE: Among several pharmacological properties, analgesia is the most common feature shared by either opioid or cannabinoid systems. Cannabinoids and opioids are distinct drug classes that have been historically used separately or in combination to treat different pain states. In the present study, we characterized the signal transduction pathways mediated by cannabinoid CB(2) and µ-opioid receptors in quiescent and LPS-stimulated murine microglial cells. EXPERIMENTAL APPROACH: We examined the effects of µ-opioid and CB(2) receptor stimulation on phosphorylation of MAPKs and Akt and on IL-1β, TNF-α, IL-6 and NO production in primary mouse microglial cells. KEY RESULTS:Morphine enhanced release of the proinflammatory cytokines, IL-1β, TNF-α, IL-6, and of NO via µ-opioid receptor in activated microglial cells. In contrast, CB(2) receptor stimulation attenuated morphine-induced microglial proinflammatory mediator increases, interfering with morphine action by acting on the Akt-ERK1/2 signalling pathway. CONCLUSIONS AND IMPLICATIONS: Because glial activation opposes opioid analgesia and enhances opioid tolerance and dependence, we suggest that CB(2) receptors, by inhibiting microglial activity, may be potential targets to increase clinical efficacy of opioids.
Authors: Malcolm Begg; Pál Pacher; Sándor Bátkai; Douglas Osei-Hyiaman; László Offertáler; Fong Ming Mo; Jie Liu; George Kunos Journal: Pharmacol Ther Date: 2005-01-11 Impact factor: 12.310
Authors: Ai-Ling Li; Xiaoyan Lin; Amey S Dhopeshwarkar; Ana Carla Thomaz; Lawrence M Carey; Yingpeng Liu; Spyros P Nikas; Alexandros Makriyannis; Ken Mackie; Andrea G Hohmann Journal: Mol Pharmacol Date: 2018-11-30 Impact factor: 4.436
Authors: Jenny L Wilkerson; Sudeshna Ghosh; Mohammed Mustafa; Rehab A Abdullah; Micah J Niphakis; Roberto Cabrera; Rafael L Maldonado; Benjamin F Cravatt; Aron H Lichtman Journal: Neuropharmacology Date: 2016-11-25 Impact factor: 5.250
Authors: Shaness A Grenald; Madison A Young; Yue Wang; Michael H Ossipov; Mohab M Ibrahim; Tally M Largent-Milnes; Todd W Vanderah Journal: Neuropharmacology Date: 2016-12-20 Impact factor: 5.250
Authors: Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman Journal: Neuropsychopharmacology Date: 2017-08-31 Impact factor: 7.853
Authors: Jenny L Wilkerson; Micah J Niphakis; Travis W Grim; Mohammed A Mustafa; Rehab A Abdullah; Justin L Poklis; William L Dewey; Hamid Akbarali; Matthew L Banks; Laura E Wise; Benjamin F Cravatt; Aron H Lichtman Journal: J Pharmacol Exp Ther Date: 2016-01-20 Impact factor: 4.030
Authors: Vishakh Iyer; Richard A Slivicki; Ana C Thomaz; Jonathon D Crystal; Ken Mackie; Andrea G Hohmann Journal: Eur J Pharmacol Date: 2020-09-05 Impact factor: 4.432